Oncology on the Move—Artios: Financing Considerations for an Early Biotech

Update: 2022-09-19

Description

Artios has raised eyebrows, and cash, raising $320 million since its founding in 2016. Led by CEO, Niall Martin, who spearheaded the development of the PARP inhibitor, Lynparza™, along with the scientific guidance of DDR pioneer, Dr. Graeme Smith, Artios has been able to make a scientific impact. However, in this episode, we will explore their financial impact, as CFO Abid Ansari details how Artios has been able survive and thrive in this challenging market environment.

Comments

In Channel

Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry

2023-10-0341:00

LifeSci Search Podcast: Episode #1

2023-03-1737:54

Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair

2023-02-1036:04

A Brief Chat with Erez Raphael, CEO of DarioHealth

2023-01-0617:41

Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs

2023-01-0530:42

A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.

2023-01-0409:51

A Brief Chat with Martin Welschof, CEO of BioInvent

2023-01-0317:22

A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.

2022-12-2911:19

A Brief Chat with Amir London, CEO of Kamada Ltd.

2022-12-2813:30

A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.

2022-12-2714:36

Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound

2022-12-1626:38

A Promising New Immune Checkpoint from Sensei Bio: VISTA

2022-12-1333:29

Turning Amino Acids into Drugs: A Novel Platform from Axcella Health

2022-12-0843:01

Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders

2022-11-1727:01

89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin

2022-11-1134:53

De-Risked Oncology Targets with Assets from Checkpoint Therapeutics

2022-11-0435:44

Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction

2022-10-2042:11

An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals

2022-09-2935:22

Oncology on the Move—Artios: Financing Considerations for an Early Biotech

2022-09-1926:55

Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

2022-09-1526:46